Insmed Appoints Two New Directors to Its Board

Will Lewis, Chair and Chief Executive Officer of Insmed

“Paul and Utpal are exceptional additions to our Board, and I am delighted to welcome them to Insmed. Paul's experience leading some of the world's largest and most complex biopharma organizations, combined with his deep commercial and strategic acumen, will be invaluable as we continue to execute our global growth strategy. Utpal brings demonstrated financial expertise and a strong track record of value creation across the biopharma industry, which will be a tremendous asset as we work to advance our pipeline and build long-term shareholder value. Together, they further strengthen our Board's capabilities at a pivotal time for Insmed, and I look forward to the perspectives and insights they will deliver.”

Paul Hudson, Independent Director of Insmed; former CEO of Sanofi and Novartis Pharmaceuticals

“Insmed is a company I have admired for years — one that has built a remarkable track record of scientific innovation, clinical execution, and commercial prowess. I am honored to join the Board at such an exciting inflection point for the Company. I look forward to leveraging my experience in global commercial strategy and organizational transformation to support Insmed's continued growth and unwavering commitment to patients.”

Utpal Koppikar, Independent Director of Insmed; CFO of Verily Health

“Insmed's pipeline, commercial momentum, and people-first culture make it a truly compelling organization. I am thrilled to join the Board and look forward to helping guide the Company's financial and operational strategy as it continues to scale its business in an effort to bring additional transformative therapies to patients in need.”